Align Technology enters $250M accelerated stock repurchase agreement

2023-02-06
并购IPO
Tempe, Arizona-based Align agreed to repurchase $250 million of its common stock. It falls under its $1 billion stock repurchase agreement announced in May 2021. The company’s most recent buyback took place in October 2022 through a $200 million repurchase with Goldman Sachs. In this agreement, two of the dental technology company’s executives personally agreed to buy significant amounts of common stock. President and CEO Joe Hogan intends to purchase $1 million. CFO and EVP of Global Finance John Morici plans to buy $200,000 in common stock. Under the terms of the repurchase, Align initially received approximately 580,000 shares of common stock. The final number of shares depends on Align’s volume-weighted stock price during the term of the deal. Align expects to complete the transaction by April 26, 2023, funding it with cash on hand. As of Dec. 31, 2022, Align had approximately 77.3 million shares outstanding and $1 billion in cash, equivalents and securities. Shares of ALGN ticked up 1.2% at $347.05 apiece as the market opened today. “We’re pleased to announce this latest $250 million ASR, which reflects the strength of our balance sheet and cash flow generation, as well as management’s and the board’s continued confidence in our ability to capitalize on the large market opportunities in our target markets and trajectory for growth,” Morici said. “Returning capital to our shareholders through stock repurchase programs while simultaneously investing in our strategic growth drivers, is consistent with our capital allocation strategy and commitment to increasing shareholder value.”
更多内容,请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
适应症
-
靶点
-
药物
-
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。